These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 11498370)

  • 21. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells.
    Choi MS; Oh JH; Kim SM; Jung HY; Yoo HS; Lee YM; Moon DC; Han SB; Hong JT
    Int J Oncol; 2009 May; 34(5):1221-30. PubMed ID: 19360335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a c-myc-dependent pathway in p53 mutant H226br non-small-cell lung cancer cell line.
    Yasuoka Y; Naomoto Y; Yamatsuji T; Takaoka M; Kimura M; Uetsuka H; Matsubara N; Fujiwara T; Gunduz M; Tanaka N; Haisa M
    Exp Cell Res; 2001 Dec; 271(2):214-22. PubMed ID: 11716533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
    Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
    Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers.
    Bode A; Dong Z
    Drug Resist Updat; 2000 Feb; 3(1):21-29. PubMed ID: 11498362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The p53 tumor suppressor: critical regulator of life & death in cancer.
    Fisher DE
    Apoptosis; 2001; 6(1-2):7-15. PubMed ID: 11321044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis.
    Gnanapradeepan K; Basu S; Barnoud T; Budina-Kolomets A; Kung CP; Murphy ME
    Front Endocrinol (Lausanne); 2018; 9():124. PubMed ID: 29695998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor suppression by p53: fall of the triumvirate?
    Hock AK; Vousden KH
    Cell; 2012 Jun; 149(6):1183-5. PubMed ID: 22682240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Contrived Mutant p53 Oncogene - Beyond Loss of Functions.
    Sabapathy K
    Front Oncol; 2015; 5():276. PubMed ID: 26697411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Approaches for Upregulation of Tumor Suppressor Proteins: Pioneering Strategies and Integrative Potentials.
    Kargbo RB
    ACS Med Chem Lett; 2024 Jun; 15(6):761-762. PubMed ID: 38894916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P53 protein and the diseases in central nervous system.
    Lei L; Lu Q; Ma G; Li T; Deng J; Li W
    Front Genet; 2022; 13():1051395. PubMed ID: 36712862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Craniotomy: the first case histories.
    Martin G
    J Clin Neurosci; 1999 Jul; 6(4):361-363. PubMed ID: 10844769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer cells use a mutant gene to enrol healthy cells into helping spread disease.
    Nurs Stand; 2016 May; 30(37):14. PubMed ID: 27206177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction: The Changing Directions of p53 Research.
    Levine AJ
    Genes Cancer; 2011 Apr; 2(4):382-4. PubMed ID: 21785490
    [No Abstract]   [Full Text] [Related]  

  • 34. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
    Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
    Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turning p53 on or off: either way may treat cancer.
    Fisher DE
    Drug Resist Updat; 2000 Apr; 3(2):77-79. PubMed ID: 11498370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
    Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.